Key Takeaways

• RNAi is a natural process where double-stranded RNA silences genes at the post-transcriptional level.
• The three main RNAi mediators are siRNA, miRNA and shRNA, each with distinct origins and roles.
• The core machinery — Drosha, Exportin-5, Dicer, TRBP and Argonaute-2 — processes RNA and loads it into the RISC complex.
• RNAi is widely used for gene knockdown, functional genomics, target validation and crop improvement.
• RNAi therapeutics are now approved for several diseases, silencing disease-causing genes directly.
• RNAi and CRISPR are complementary: RNAi knocks genes down reversibly, CRISPR edits DNA permanently.

Contents

• What is RNA Interference?
• The RNAi Machinery
• Types of RNAi: siRNA, miRNA & shRNA
• How Does RNA Interference Work?
• RNAi vs CRISPR
• Applications of RNAi
• RNAi Therapeutics
• The Future of RNAi
• Frequently Asked Questions

RNAi Pathway ELISA Kits & Antibodies

These validated immunoassays and antibodies target the core enzymes of the RNA interference pathway, from nuclear processing through to RISC-mediated silencing.

Human Drosha ELISA Kit

The nuclear RNase III enzyme that crops primary miRNA transcripts into precursor miRNA, the first step of miRNA biogenesis.

View kit →

Exportin-5 Antibody

Exportin-5 (XPO5) transports precursor miRNA from the nucleus to the cytoplasm for further processing.

View antibody →

Human Dicer (DICER1) ELISA Kit

The cytoplasmic RNase III enzyme that dices long double-stranded RNA and pre-miRNA into mature siRNA and miRNA duplexes.

View kit →

Human TRBP / TARBP2 ELISA Kit

A RISC-loading complex subunit that partners with Dicer to hand processed RNA duplexes to Argonaute.

View kit →

Human Argonaute-2 (AGO2) ELISA Kit

The catalytic core of RISC — the slicer endonuclease that cleaves target mRNA guided by the loaded RNA strand.

View kit →

Human Bcl-2 ELISA Kit

A representative therapeutic knockdown target; siRNA against the Bcl-2 oncogene induces apoptosis in cancer cells.

View kit →

What is RNA Interference?

RNA interference, also referred to as post-transcriptional gene silencing (PTGS), is the process by which RNA molecules silence the expression of specific genes in response to double-stranded RNA. First described in the nematode Caenorhabditis elegans by Andrew Fire and Craig Mello — work that earned them the 2006 Nobel Prize in Physiology or Medicine — RNAi is now recognised as a fundamental and evolutionarily conserved mechanism of gene regulation found across plants, animals and fungi.

At its heart, RNAi works by matching a short guide RNA to a complementary messenger RNA (mRNA) sequence and then triggering that mRNA’s destruction or translational repression. Because the guide sequence can be designed to match almost any gene, RNAi gives researchers a programmable way to switch off individual genes and observe the consequences — making it indispensable for studying gene function, validating drug targets, and, increasingly, treating disease.

The RNAi Machinery

A small set of specialised proteins drives every RNAi event, working in sequence from the nucleus to the cytoplasm. Understanding this machinery is essential to interpreting knockdown experiments and to developing RNAi-based drugs.

In the nucleus, the RNase III enzyme Drosha, together with its partner DGCR8, crops long primary miRNA transcripts into hairpin-shaped precursor miRNAs. Exportin-5 then shuttles these precursors into the cytoplasm. There, a second RNase III enzyme, Dicer, cleaves the double-stranded RNA into short 21–23 nucleotide duplexes. Dicer works with the RNA-binding protein TRBP (encoded by TARBP2) to load one strand of the duplex into Argonaute-2 (AGO2), the catalytic engine of the RNA-induced silencing complex (RISC). AGO2 uses the loaded guide strand to find and, in the case of perfect complementarity, cleave the target mRNA.

Types of RNAi: siRNA, miRNA & shRNA

Three classes of small RNA mediate interference, each with a distinct origin but a shared downstream mechanism.

Small interfering RNA (siRNA)

siRNA is a double-stranded RNA molecule, typically 20–25 nucleotides long, that is either synthesised artificially or produced when Dicer cleaves longer double-stranded RNA. It acts as a highly specific guide, pairing with a complementary mRNA and triggering its degradation by RISC. siRNA usually silences a single, perfectly matched target.

MicroRNA (miRNA)

miRNAs are endogenous, single-stranded RNAs of about 21–23 nucleotides, transcribed from the genome and processed by Drosha and Dicer. Because they bind their targets with only partial complementarity, a single miRNA can regulate many different mRNAs, fine-tuning entire gene networks during development and homeostasis.

Short hairpin RNA (shRNA)

shRNA is an artificial RNA with a tight hairpin fold that is expressed from a DNA vector inside the cell. It is processed into siRNA by the endogenous machinery, providing stable, long-term gene knockdown — an advantage over transiently delivered siRNA.

How Does RNA Interference Work?

The silencing process follows a defined sequence of events. Long double-stranded RNA or precursor miRNA is first cleaved by Dicer into short duplexes. One strand — the guide strand — is loaded into Argonaute-2 within RISC, while the other (passenger) strand is discarded. The activated RISC then scans the cytoplasm for messenger RNAs complementary to its guide.

When the match is perfect, AGO2 cleaves the target mRNA, which is then degraded, preventing translation. When the match is only partial — as is typical for miRNA — RISC instead blocks translation and promotes mRNA destabilisation. Either way the outcome is the same: the protein encoded by the target gene is no longer made, and the gene is effectively silenced. This can also occur at the transcriptional level, where RNAi directs chromatin modification and epigenetic silencing of the target locus.

RNAi vs CRISPR

RNAi and CRISPR are often compared because both allow researchers to suppress gene function, but they act at different levels and are best seen as complementary rather than competing tools.

Applications of RNAi

RNAi has become a cornerstone technique across the life sciences because it offers a fast, specific and programmable way to reduce the expression of almost any gene.

Gene function studies

By silencing a gene of interest and observing the resulting phenotype, researchers can infer that gene’s role in a cellular process or disease pathway — a strategy known as loss-of-function analysis.

Functional genomics

Genome-wide RNAi screens systematically knock down thousands of genes in parallel, identifying those involved in processes such as cell division, apoptosis or drug resistance.

Crop improvement

In agriculture, RNAi is used to silence genes that control ripening, allergen content or pest susceptibility, producing more resilient and higher-quality crops.

RNAi Therapeutics

Beyond the laboratory, RNAi has matured into a genuine therapeutic modality. By designing siRNAs against disease-causing genes, clinicians can silence targets that were previously considered “undruggable” by conventional small molecules or antibodies.

RNAi is a promising strategy for a wide range of conditions, including Alzheimer’s disease, Huntington’s disease and cancer. In neurodegeneration, siRNAs targeting the Huntington gene can raise levels of brain-derived neurotrophic factor (BDNF), a protein that protects neurons. In oncology, siRNAs against the oncogene Bcl-2 have been shown to induce apoptosis in cancer cells, and several approved RNAi drugs now treat rare metabolic and cardiovascular diseases by silencing hepatic targets.

The Future of RNAi

The main challenges for RNAi have always been delivery and specificity: getting the RNA into the right cells and avoiding off-target silencing. Advances in chemical modification, lipid nanoparticle and GalNAc conjugate delivery, and improved guide-strand design are steadily solving these problems, expanding the range of tissues and diseases that RNAi can reach.

As delivery improves, RNAi is likely to move beyond rare liver-targeted diseases into more common conditions, and to sit alongside CRISPR and antisense oligonucleotides as a core part of the RNA-based therapeutic toolkit.